Your browser doesn't support javascript.
loading
Machine learning-based classification of Alzheimer's disease and its at-risk states using personality traits, anxiety, and depression.
Waschkies, Konrad F; Soch, Joram; Darna, Margarita; Richter, Anni; Altenstein, Slawek; Beyle, Aline; Brosseron, Frederic; Buchholz, Friederike; Butryn, Michaela; Dobisch, Laura; Ewers, Michael; Fliessbach, Klaus; Gabelin, Tatjana; Glanz, Wenzel; Goerss, Doreen; Gref, Daria; Janowitz, Daniel; Kilimann, Ingo; Lohse, Andrea; Munk, Matthias H; Rauchmann, Boris-Stephan; Rostamzadeh, Ayda; Roy, Nina; Spruth, Eike Jakob; Dechent, Peter; Heneka, Michael T; Hetzer, Stefan; Ramirez, Alfredo; Scheffler, Klaus; Buerger, Katharina; Laske, Christoph; Perneczky, Robert; Peters, Oliver; Priller, Josef; Schneider, Anja; Spottke, Annika; Teipel, Stefan; Düzel, Emrah; Jessen, Frank; Wiltfang, Jens; Schott, Björn H; Kizilirmak, Jasmin M.
Affiliation
  • Waschkies KF; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Soch J; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
  • Darna M; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Richter A; Bernstein Center for Computational Neuroscience, Berlin, Germany.
  • Altenstein S; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Beyle A; Leibniz Institute for Neurobiology, Magdeburg, Germany.
  • Brosseron F; Leibniz Institute for Neurobiology, Magdeburg, Germany.
  • Buchholz F; German Center for Mental Health (DZPG), Munich, Germany.
  • Butryn M; Center for Intervention and Research on Adaptive and Maladaptive Brain Circuits Underlying Mental Health (C-I-R-C), Jena-Magdeburg-Halle, Germany.
  • Dobisch L; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Ewers M; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Fliessbach K; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Gabelin T; Department of Neurology, University of Bonn, Bonn, Germany.
  • Glanz W; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Goerss D; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Gref D; Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Janowitz D; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Kilimann I; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Lohse A; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Rauchmann BS; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Rostamzadeh A; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Roy N; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany.
  • Spruth EJ; Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Dechent P; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Heneka MT; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Hetzer S; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Ramirez A; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Scheffler K; Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Buerger K; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Laske C; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Perneczky R; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Peters O; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Schneider A; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Spottke A; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Teipel S; Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
  • Düzel E; Department of Neuroradiology, University Hospital LMU, Munich, Germany.
  • Jessen F; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
  • Wiltfang J; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Schott BH; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Kizilirmak JM; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
Int J Geriatr Psychiatry ; 38(10): e6007, 2023 10.
Article in En | MEDLINE | ID: mdl-37800601
ABSTRACT

BACKGROUND:

Alzheimer's disease (AD) is often preceded by stages of cognitive impairment, namely subjective cognitive decline (SCD) and mild cognitive impairment (MCI). While cerebrospinal fluid (CSF) biomarkers are established predictors of AD, other non-invasive candidate predictors include personality traits, anxiety, and depression, among others. These predictors offer non-invasive assessment and exhibit changes during AD development and preclinical stages.

METHODS:

In a cross-sectional design, we comparatively evaluated the predictive value of personality traits (Big Five), geriatric anxiety and depression scores, resting-state functional magnetic resonance imaging activity of the default mode network, apoliprotein E (ApoE) genotype, and CSF biomarkers (tTau, pTau181, Aß42/40 ratio) in a multi-class support vector machine classification. Participants included 189 healthy controls (HC), 338 individuals with SCD, 132 with amnestic MCI, and 74 with mild AD from the multicenter DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE).

RESULTS:

Mean predictive accuracy across all participant groups was highest when utilizing a combination of personality, depression, and anxiety scores. HC were best predicted by a feature set comprised of depression and anxiety scores and participants with AD were best predicted by a feature set containing CSF biomarkers. Classification of participants with SCD or aMCI was near chance level for all assessed feature sets.

CONCLUSION:

Our results demonstrate predictive value of personality trait and state scores for AD. Importantly, CSF biomarkers, personality, depression, anxiety, and ApoE genotype show complementary value for classification of AD and its at-risk stages.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Int J Geriatr Psychiatry Journal subject: GERIATRIA / PSIQUIATRIA Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Int J Geriatr Psychiatry Journal subject: GERIATRIA / PSIQUIATRIA Year: 2023 Type: Article Affiliation country: Germany